HomeAI · summaries
Storia in 6 fonti
Regeneron to challenge Ipsen as FDA clears bone disease drug
Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Regeneron drug for disease that causes dangerous bone growth earns FDA approval
A Regeneron drug that treats an ultra-rare disease that causes bone to form where it's not meant to be has won approval.
- ·
fiercepharma.com
Regeneron's Pasatru scores FDA approval in ultrarare bone lesions disorder
After more than 10 years in development, Regeneron secured a landmark approval for its monoclonal antibody garetosmab, now commercially known as Pasatru. | Regeneron's Pasatru has…
